Package Leaflet: Information for the User
RELPAX 40mg Film-Coated Tablets
Read this leaflet carefully before you start taking this medicine,because it contains important information for you.
6. Contents of the pack and additional information
Relpax contains eletriptan as the active ingredient. Relpax belongs to a group of medicines called serotonin receptor agonists. Serotonin is a natural substance found in the brain that helps to constrict blood vessels.
Relpax can be used for the treatment of migraine headache with or without aura in adults. Before a migraine headache begins, you may experience a phase called “aura”, in which you may experience visual disturbances, numbness, and language alterations.
Inform your doctor and do not take Relpax, if you have any of these circumstances currently or if you have had them in the past.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Relpax if:
Repeated use of migraine medications
If you repeatedly use Relpax or any other migraine medication for several days or weeks, this may cause long-lasting daily headaches. Inform your doctor if you have experienced this, as you may need to interrupt treatment for a time.
Use of Relpax with other medications
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
Taking Relpax with some medications may cause severe adverse effects. Do not take Relpax if:
Some medications may affect how Relpax works, or Relpax itself may reduce the effectiveness of other medications taken at the same time. This includes:
Preparations based on St. John's Wort (Hypericum perforatum) should not be taken at the same time as this medication. If you are already taking St. John's Wort, consult your doctor before stopping the preparation.
Inform your doctor before starting treatment with eletriptan, if you are taking some medications (commonly known as ISRSs* or IRSNs**) for depression or other mental disorders. These medications may increase the risk of developing serotonin syndrome when used in combination with certain medications for migraine. See Section 4 “Possible adverse effects” for more information on the symptoms of serotonin syndrome.
*ISRSs – Selective serotonin reuptake inhibitors.
**IRSNs – Serotonin and noradrenaline reuptake inhibitors.
Taking Relpax with food and drinks
Relpax can be taken before or after consuming food and drinks.
Pregnancy and breastfeeding
Consult your doctor or pharmacist before using any medication.
If you are pregnant or breastfeeding, think you may be pregnant, or intend to become pregnant, consult your doctor before using this medication.
It is recommended to avoid breastfeeding in the 24 hours following the intake of this medication.
Driving and operating machinery
Relpax, or the migraine itself, may cause drowsiness. This medication may also cause dizziness. For this reason, you should avoid driving and operating machinery during a migraine attack or after taking the medication.
Relpax contains lactose, aluminium lake of yellow-orange colour (E110) and sodium
Lactose is a type of sugar.This medication contains lactose.If your doctor has told you that you have a certain sugar intolerance, consult with them before taking this medication.
This medication may cause allergic reactions because it contains aluminium lake of yellow-orange colour (E110). It may cause asthma, especially in patients allergic to acetylsalicylic acid.
This medication contains less than 23 mg of sodium (1 mmol) per tablet; it is essentially “sodium-free”.
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Adults
You can take the medication at any time after the onset of migraine headache, but it is best to take it as soon as possible. However, you should only take Relpax during the headache phase of migraine. Do not take this medication to prevent a migraine attack.
Use in childrenand adolescents under 18 years
Relpax tablets are not recommended for use in children and adolescents under 18 years.
Over 65 years
Relpax tablets are not recommended for use in patients over 65 years.
Renal insufficiency
This medication can be used in patients with mild or moderate kidney problems. In these patients, the initial recommended dose is 20mg (one Relpax 20mg tablet) and the total daily dose should not exceed 40mg (two Relpax 20mg tablets or one Relpax 40 mg tablet).
Liver insufficiency
This medication can be used in patients with mild or moderate liver problems. No dose adjustments are required for mild or moderate liver insufficiency.
If you take more Relpax than you should
If you accidentally take more Relpax than you should, contact your doctor immediately or go to the nearest hospital emergency room. Always carry the medication packaging with you, even if it is empty. The adverse effects of Relpax overdose include high blood pressure and heart problems.
Consult your doctor, pharmacist, or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount taken.
It is recommended to bring the packaging and the medication leaflet to the healthcare professional.
If you forgot to take Relpax
If you forgot to take a dose, take it as soon as you remember, unless it is almost time for the next dose. Do not take a double dose to compensate for the missed doses.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
Inform your doctor immediatelyif you experience any of the following symptoms after taking the medicine.
Other side effects that may occur are:
Frequent side effects:
(may affect up to 1 in 10 people)
Infrequent side effects:
(may affect up to 1 in 100 people))
Rare side effects:
(may affect up to 1 in 1,000 people))
Other side effects reported include fainting, high blood pressure, inflammation of the large intestine, vomiting,vascular and cerebral accidents, inadequate heart blood flow, heart attack, spasm of the arteries and heart muscles.
Your doctor may make regular blood tests to examine increased liver enzymes or any blood problems.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging. The expiration date is the last day of the month indicated.
PVC/Aclar/Aluminum Blister Packs: No special storage conditions are required.
HDPE Bottles: Store in the original packaging. Keep the packaging perfectly closed to protect it from moisture.
Medications should not be disposed of through drains or in the trash. Deposit the packaging and medications you no longer need at the SIGRE collection point at the pharmacy.If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Relpax 40 mg film-coated tablets
The active ingredient is eletriptan (as eletriptan hydrobromide).
Each Relpax 40 mg film-coated tablet contains 40 mg of eletriptan (in the form of hydrobromide).
The other components are: microcrystalline cellulose, lactose monohydrate, sodium croscarmellose, magnesium stearate, titanium dioxide (E-171), hypromellose, glycerol triacetate, and aluminium lake of yellow-orange FCF (E-110) (see section 2).
Appearance of the product and content of the container
Relpax tablets are orange, round, film-coated tablets.
Relpax 40 mg film-coated tablets are marked with “VLE” on one face and “REP 40” on the other.
Relpax is presented in opaque PVC/Aclar/Aluminium blisters containing 2, 3, 4, 5, 6, 10, 18, 30, and 100 tablets or in HDPE bottles with a HDPE/PP child-resistant closure containing 30 and 100 tablets.
Only some container sizes may be marketed.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder
Viatris Healthcare, S.L.
General Aranaz Street, 86,3rd floor
28027 Madrid
Spain
Responsible manufacturer
Pfizer Italia S.r.l.,
Marino del Tronto
63100 Ascoli Piceno
Italy
Local Representative
Viatris Pharmaceuticals, S.L.U.
General Aranaz Street, 86
28027 Madrid
Spain
This medicine is authorized in the member states of the European Economic Area under the following names:
Relert 20 mg and 40 mg film-coated tablets: Belgium, Finland, Luxembourg, Portugal, Spain, United Kingdom.
Relpax 20 mg and 40 mg film-coated tablets: Austria, Denmark, France, Germany, Greece, Iceland, Ireland, Italy, Norway, Spain, Sweden, Netherlands, United Kingdom.
Last review date of this leaflet: January 2021
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.